Shots:

• The US FDA has approved Entadfi for the treatment of the signs and symptoms of urinary tract symptoms caused by a BPH in men with an enlarged prostate for ~26wks. The therapy is expected to be available in early 2022
• Entadfi has also been shown to be more effective to treat urinary tract symptoms caused by BPH & has less potential for adverse sexual side effects compared to finasteride monothx.
• Entadfi combines finasteride (5α-reductase inhibitor) and tadalafil (PDE5 inhibitor) into 1 capsule formulation. Additionally, The therapy will be marketed and distributed by Veru to patient telemedicine and telepharmacy services platform

Ref: Globe Newswire | Image: Veru